Canada’s government says it will make a public announcement on Thursday about the safety and efficacy of the new hepatitis C vaccines, with the hope of sparking a broader debate on vaccination policies and the safety of other vaccines.
The announcement, to be made in Toronto at 2 p.m., is expected to take place at the National Archives, which holds a record of all the governments, provinces and territories that have received vaccines and have tested them.
Since Canada became the first developed country to announce its first public-health initiative to vaccinate against the hepatitis C virus, its public health officials have been grappling with questions about whether there is a link between the vaccines and a possible connection between the two infections.
Canadian health officials say the hepatitis A vaccine is not linked to the two cases in the U of T. Vaccination coverage has been falling in Canada, and the new vaccine is expected by late 2019.
Hepatitis C is the second-most common chronic liver disease in the country, and is caused by the hepatitis B virus.
It’s also one of the leading causes of liver cancer.
“We want to start a conversation about the importance of hepatitis C vaccination, especially when it comes to addressing the public health burden of the virus,” Health Minister Rona Ambrose told reporters on Thursday.
“That’s why we’re making this announcement.”
“As the number of cases in Canada continues to decline, we need to look at how we can take additional steps to reduce the transmission of hepatitis A, as well as other infectious agents that may be present in the population.”
Ambrose noted the hepatitis vaccine has not been available in the United States for more than a decade, but she said the vaccine was available in Britain for several years.
U.S.-born Canadians also have a higher rate of the infection than their Canadian counterparts.
At least 2.5 million people are infected with the virus, according to a recent survey by the Centers for Disease Control and Prevention.
CDC Director Tom Frieden, speaking at a news conference on Friday, said the U.”s high rate of infection means that we need additional vaccines that have been developed and tested and that are safe and effective.”
He also pointed to the fact that the vaccine used in the Toronto event will be manufactured in the USA, a country where there is no vaccine for the virus.
“We need to ensure that the vaccines we make are safe, effective and accessible to Canadians,” Frieden said.
“We need a vaccine that is available in all the countries of the world.
If you can’t get it in the US, you need to get it from another country.”
Hendrik Zilles, a researcher at the University of Toronto, said a public health conversation about hepatitis C is “in a very different place now” than it was before the pandemic.
Zilles noted that the hepatitis I vaccine was approved in the UK, where it has been widely available for about 15 years.
The U.K. is the only country in the world to have used it, and it has a much lower rate of hepatitis than Canada, he said.
He said a recent study in England showed that the U., as well, has a lower prevalence of the disease than the U, even though both countries have more than 90 million people.
But Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told the Associated Press that the numbers are still low.
While there are some countries where the U is still the only nation in the developed world where the vaccine is available, he added that the current rates are far below those in most developed countries.
Fauci said the virus is not spreading to the U and that most of the cases are in countries that are still recovering from the pandemics.
In the United Kingdom, for example, the number is less than one in 20, he noted.
A Canadian government spokesperson said the announcement will be made by the Ministry of Health and Social Development.
On Thursday, the country’s chief medical officer, Dr. John Daley, told reporters that he expects the U to make its announcement within the next couple of weeks.
Dr. James McPherson, a senior research fellow at the Canadian Centre for Policy Alternatives, said Canada has made “a strong commitment to the health of its citizens and has been doing very well.”
McPhersons work focuses on how health care systems respond to the pandemaker and on the risks of vaccines.
He said it is possible that a similar public-awareness effort could be needed in the future.
McGregor, the Canadian Vaccine Advocacy Centre’s executive director, told Recode that the government should start “thinking about ways that the system can address the needs of Canadians, not just the number